Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Edgewise Therapeutics Inc

EWTX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$43.07

▲ +2.67%

Market Cap $4.68B · Vol 256.23K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.68B

Mid Cap

Div Yield

N/A

EPS Growth

+179.03%

YoY

RSI (14)

46.01

Momentum

Beta

0.35

vs Market

52W High

$48.40

11.01% below

52W Low

$13.69

214.72% above

Volume

256.23K

Avg 370.90K

P/B

5.05

Price-to-book

ROE

-34.19%

Return on equity

Free Float

81.19%

Public shares

Shariah Compliance8 STANDARDS

✗ Edgewise Therapeutics Inc (EWTX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EWTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.72%

-3.66%

+15.69%

+49.13%

YTD

+73.56%

+194.60%

+559.57%

+158.37%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-167,795,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-34.19%
ROA · ROIC	-32.29% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.05
P/FCF	N/A
EPS Growth	+179.03%
Outstanding Shares	108.60M

Technical Indicators

50-Day SMA	$42.24
200-Day SMA	$32.98
RSI (14)	46.01
Beta	0.35
52-Week High	$48.40
52-Week Low	$13.69

Volume Today	256.23K
Avg Daily Volume (30D)	370.90K
Relative Volume	0.69x
Volatility (10D)	26.20
Volatility (30D)	60.10
Free Float	81.19%

Analyst Consensus

BUY

Current Price $43.07

Mean Target $51.00

52W Low$13.69 52W High$48.40

Current

Target

$13.69 $48.40

Current Analyst target

+18.41% upside potential · 13 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00K4Y2H33

ISINUS28036F1057

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.57% ARGX.BR argenx SE -2.06% ARGX argenx SE -1.93% INSM Insmed Inc -0.31% 2269.HK WuXi Biologics (Cayman) Inc -3.00%

Company Profile

Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.